Trial Profile
Phase II Trial Of Yttrium-90-Ibritumomab Tiuxetan (Zevalin®) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary) ; Cisplatin; Cytarabine; Etoposide; Methylprednisolone; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 15 Feb 2019 Status changed from active, no longer recruiting to completed.
- 12 Apr 2018 Planned End Date changed from 31 Dec 2018 to 31 Dec 2019.
- 12 Apr 2018 Planned primary completion date changed from 31 Dec 2017 to 31 Dec 2018.